BostonGene will present six research abstracts at EHA 2026, highlighting how AI-powered multiomics analysis and immune profiling are transforming blood cancer research. Developed in collaboration with leading cancer centers and academic institutions, these studies demonstrate the potential of predictive modeling, biomarker discovery, and integrated genomic analysis to improve risk stratification, predict treatment response, and support more personalized therapeutic strategies. The findings reinforce the growing role of AI in advancing precision medicine and optimizing clinical decision-making in hematologic malignancies.